Pharma M&A: Agile Shouldn’t Mean Ad Hoc

Exhibit 1 Companies with CEO very involved in M&A processes

by McKinsey & Company
Under pressure to be active acquirers, some pharmaceutical and medical-products companies may be neglecting best practices. Here’s where they can most improve. The spate of recent megamergers among both pharmaceutical and medical-products (PMP) companies has made for eye-opening headlines, not just for the supersizing of these industry-consolidating deals, but also because it seemed to mark a break from the industry’s usual pattern of M&A. […] Read more

Deal Tectonics: At The Fault Line Of Growth Goals And Competitive Pressures

Exhibit 1: Record M&A: a new normal

by Ernst & Young
As the specialty pharmaceutical sector sees its ability to pursue large acquisitions evaporate, long-promised organic growth from big pharma new drug launches has finally arrived. But a renewed focus on value-based pricing, staunch competition across key therapeutic battlefields and consolidating payer clout may weaken the industry’s ability to reach revenue targets for both new and legacy therapeutics. […] Read more

When Do Acquirers Invest In The R&D Assets Of Acquired Science-Based Firms In Cross-Border Acquisitions?

Table 1 Sample firm characteristics

by Elsevier Ltd.
Drawing on a multiple case study of acquisitions of UK biopharmaceutical firms, we develop an analytical framework that elucidates how key determinants of the knowledge base of science-based firms and their combinations through M&As interact and affect post-acquisition investment in the target’s R&D projects. […] Read more

Dealing With Uncertainty: Strategies For Overcoming Compliance Risk And Regulatory Challenges In Cross-Border M&A

Figure 1 Pharmerging Markets

by Baker & McKenzie
When you look at the numbers, there’s no question why global pharmaceutical companies have set their sights on emerging markets for future growth. From 2012 to 2017, global pharmaceutical sales are expected to rise 13% in the “pharmerging markets,” compared to 2% for the top mature markets, according to the IMS Institute for Healthcare Informatics. […] Read more

Pharmaceutical Sector: M&A Insights 2006-2007

by PricewaterhouseCoopers
2006 and the first half of 2007 saw a significant increase in M&A activity in the global pharmaceutical and healthcare sectors, continuing the upward trend exhibited in recent years. Altogether in 2006 there were 2,111 deals across the pharma/medical devices/healthcare services sectors with a total deal value in excess of $209bn compared with 2,048 deals with a total deal value of $152bn in 2005. […] Read more

Pharmaceutical Sector: M&A Insights 2006-2007

by PricewaterhouseCoopers
2006 and the first half of 2007 saw a significant increase in M&A activity in the global pharmaceutical and healthcare sectors, continuing the upward trend exhibited in recent years. Altogether in 2006 there were 2,111 deals across the pharma/medical devices/healthcare services sectors with a total deal value in excess of $209bn compared with 2,048 deals with a total deal value of $152bn in 2005. […] Read more

Pharmaceutical Sector: M&A Insights 2006-2007

by PricewaterhouseCoopers
2006 and the first half of 2007 saw a significant increase in M&A activity in the global pharmaceutical and healthcare sectors, continuing the upward trend exhibited in recent years. Altogether in 2006 there were 2,111 deals across the pharma/medical devices/healthcare services sectors with a total deal value in excess of $209bn compared with 2,048 deals with a total deal value of $152bn in 2005. […] Read more

Pharmaceutical Sector: M&A Insights 2005-2006

by PricewaterhouseCoopers
M&A activity in the pharmaceutical and healthcare sector remained buoyant during 2005 with the completion of 2,048 transactions totalling $152bn. This tally – which encompasses deals worldwide in the pharmaceuticals, medical devices and healthcare services segments – compares with 1,807 transactions worth a combined $146bn in 2004. […] Read more

Pharmaceutical Sector: M&A Insights 2005-2006

by PricewaterhouseCoopers
M&A activity in the pharmaceutical and healthcare sector remained buoyant during 2005 with the completion of 2,048 transactions totalling $152bn. This tally – which encompasses deals worldwide in the pharmaceuticals, medical devices and healthcare services segments – compares with 1,807 transactions worth a combined $146bn in 2004. […] Read more

Are you sure you
want to log out?

Request a Brochure

Request a Brochure

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!

Book a Demo

Book a Demo

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!